Enterprise Ireland and Northwell Health have formalised a new strategic alliance aimed at advancing Irish medtech expansion in the U.S., reinforcing an already established collaboration between the two organisations. The agreement, announced during a St. Patrick’s Day ceremony in New York, signals a continued effort to accelerate the commercialisation and scale-up of Irish life sciences and medtech companies across the American healthcare landscape.
Northwell, one of the largest U.S. health systems, is already working with 18 Enterprise Ireland companies, with existing engagements delivering procurement contracts, clinical pilots and trials, as well as strategic investments. Under the renewed framework, Enterprise Ireland client companies will retain direct access to Northwell’s clinical experts spanning 28 hospitals and more than 1,000 outpatient facilities. In addition, companies will be able to leverage Northwell’s innovation ecosystem and commercial infrastructure, strengthening pathways for Irish medtech expansion in a competitive global market.
The announcement aligns with Enterprise Ireland’s broader strategy to grow the Irish medtech sector internationally, following its end-of-2025 report highlighting sector expansion. Alongside this partnership, Galway-based Neurent Medical, supported by Enterprise Ireland, has also entered into an agreement with Northwell. Neurent develops the Neuromark system for treating chronic rhinitis, a device designed with a flexible shaft and atraumatic leaflets to conform to patient anatomy and reach difficult areas within the nasal cavity. The system delivers impedance-controlled, low-power radiofrequency (RF) energy to disrupt parasympathetic nerve signals, addressing symptoms such as persistent nasal congestion and rhinorrhea (runny nose). The next-generation Neuromark system received FDA clearance in June 2025, while Neurent raised $74 million (€62.5 million) in an oversubscribed Series C financing round earlier this year. With a U.S. headquarters in Braintree, Massachusetts, the company aims to scale further through this collaboration.
Enterprise Ireland also highlighted a broader wave of U.S. expansion by Irish firms, including Shorla Oncology, Fire1, Head Diagnostics and X-Bolt. These companies are strengthening their commercial, clinical and partnership footprints across the U.S., reflecting continued momentum in Ireland’s life sciences ecosystem. Government and industry leaders underscored the importance of such partnerships in enabling Irish innovation to reach global markets.
“Northwell Health has been an invaluable partner to Ireland and to Irish health tech and medtech companies. This alliance has provided Irish companies with unparalleled opportunities and privileged access to Northwell Health’s vast clinical network, serving as a critical gateway for innovative Irish companies entering and scaling within the U.S. healthcare market. Ireland’s life sciences and health tech sector is thriving, and partnerships like this are central to ensuring that innovation emerging from Ireland reaches patients in the U.S. and around the world.”
“Northwell Health is proud to sign this new strategic alliance with Enterprise Ireland and build upon years of successful collaboration. Our International Business Program has proven to be an invaluable gateway for innovative international companies seeking to enter and scale within the U.S. healthcare market. Since 2016, we have provided Enterprise Ireland client companies with direct access to clinical experts across one of America’s largest health systems, resulting in meaningful outcomes including procurement contracts, clinical pilots and trials, and strategic investments from Northwell Ventures. We look forward to welcoming the next generation of Irish healthcare innovators and supporting their growth in the U.S. market.”
